First-line SGLT2 inhibitors lower risk for heart failure hospitalization vs. metformin

For patients with type 2 diabetes, first-line SGLT2 inhibitors might be better than metformin when it comes to their cardiovascular health, according to results of a population-based cohort study.
Since 2018, SGLT2 inhibitors have been endorsed as a second-line treatment for type 2 diabetes and have recently been recommended as a first-line treatment, HoJin Shin, BPharm, PhD, a postdoctoral research fellow at Brigham and Women’s Hospital, and colleagues wrote in Annals of Internal Medicine.
The researchers analyzed claims data from two large U.S. commercial and Medicare databases from

For patients with type 2 diabetes, first-line SGLT2 inhibitors might be better than metformin when it comes to their cardiovascular health, according to results of a population-based cohort study.
Since 2018, SGLT2 inhibitors have been endorsed as a second-line treatment for type 2 diabetes and have recently been recommended as a first-line treatment, HoJin Shin, BPharm, PhD, a postdoctoral research fellow at Brigham and Women’s Hospital, and colleagues wrote in Annals of Internal Medicine.
The researchers analyzed claims data from two large U.S. commercial and Medicare databases from